Description
Tacrolimus Alkaline Phosphatase Conjugate
| Catalog number: | B2010725 |
| Lot number: | Batch Dependent |
| Expiration date: | Batch Dependent |
| Amount: | 0.1 mg |
| Concentration: | 0.2 mg/mL |
| Supplied as: | Liquid |
| Storage: | 20C |
| Keywords: | Tacrolimus-ALP, Tacrolimus-AP, Tacrolimus-Alkaline Phosphatase |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 Mcm) and are filtered through 0.22 m. |
Tacrolimus Alkaline Phosphatase Conjugate is a high-performance reagent designed for enzymatic detection of tacrolimus (FK506), a potent immunosuppressant widely used in organ transplantation and autoimmune disease management. This conjugate features tacrolimus covalently linked to alkaline phosphatase (AP), enabling sensitive colorimetric or chemiluminescent detection in immunoassay platforms such as ELISA and CLIA.
Alkaline phosphatase is a robust enzyme that catalyzes the hydrolysis of phosphate esters, producing measurable signals in diagnostic assays. When conjugated to tacrolimus, it facilitates the development of competitive immunoassays for therapeutic drug monitoring (TDM), pharmacokinetic profiling, and toxicity screening. The reagent is supplied at 0.2 mg/mL in liquid format and is compatible with both manual and automated workflows.
This conjugate is particularly useful in transplant medicine, nephrology, and personalized dosing research. It supports assay development for tacrolimus quantification in serum, plasma, and whole blood, and is formulated in ultrapure water and filtered through 0.22 m membranes to ensure purity and reproducibility.
Key benefits:
- Tacrolimus conjugated to alkaline phosphatase for enzymatic detection
- Supports ELISA, CLIA, and other immunoassay platforms
- Optimized for therapeutic drug monitoring and assay development
- Biotechnology grade; filtered through 0.22 m membranes
- Supplied at 0.2 mg/mL; store at 20C to maintain activity
Products are for in vitro research use only (RUO).
References
- First MR, Fitzsimmons WE. Modified release tacrolimus. Yonsei Med J. 2004 Dec;45(6):11271131.
- Jouve T et al. Safety of tacrolimus in kidney transplant recipients. Expert Opin Drug Saf. 2019 Apr;18(4):285294.
- Kalt DA. Laboratory detection methods for tacrolimus. Lab Med. 2017 Nov;48(4):e62e65.
- Zhai J et al. Tacrolimus in ocular disease treatment. BioDrugs. 2011 Apr;25(2):89103.
- Tacrolimus. Am J Health Syst Pharm. 2001 Dec;58(24):23762377.
- Uemoto S. [Tacrolimus]. Nihon Rinsho. 2005 May;63 Suppl 5:673677.
- Radhakrishnan A et al. Personalization of tacrolimus therapy. Pharmacogenomics. 2021 Nov;22(17):11511175.
- Schreiber SL. Molecular glues and tacrolimus. Cell. 2021 Jan;184(1):39.
- Pennington CA, Park JM. Sublingual tacrolimus in transplant recipients. Am J Health Syst Pharm. 2015 Feb;72(4):277284.
- Zhang X et al. Pharmacogenetic considerations in tacrolimus dosing. Biomed Pharmacother. 2018 Jun;102:107114.
